Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hoth Therapeutics, Inc. - Common Stock (NQ:HOTH)

1.490 +0.060 (+4.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hoth Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
FDA Signs Off Hoth Therapeutics' Trial Application For HT-001 For Skin Cancers
Via Benzinga
Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer's Program
Via Benzinga
Nasdaq Jumps Over 250 Points; Crude Oil Down 1%
U.S. stocks traded higher midway through trading, with the Dow Jones climbing around 400 points on Thursday. 
Via Benzinga
Dow, Nasdaq Up Triple Digits In Latest Last-Ditch Rally
Stocks are attempting a last-minute rally before the year comes to a close, as investors react to higher-than-expected jobless claims data. 
Via Talk Markets
Dow Surges 250 Points; Jobless Claims Rise To 225,000
U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who... 
Via Benzinga
Why Entrada Therapeutics Shares Are Trading Lower By 32%; Here Are 31 Stocks Moving Premarket
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small... 
Via Benzinga
Why Is Hoth Therapeutics (HOTH) Stock Up 24% Today?
Hoth Therapeutics (HOTH) stock is rising higher on Monday with heavy trading and positive results from a Phase 1 clinical trial of BioLexa. 
Via InvestorPlace
Why Global Payments Shares Are Trading Lower By Around 8%? Here Are 41 Stocks Moving In Monday's Mid-Day Session
Gainers 1847 Holdings LLC (NASDAQ: EFSH) shares surged 72.7% to $3.25 after the company reported it sees over $60 million in revenue and over $7 million in cash flow from operations in 2023 from its... 
Via Benzinga
Nasdaq Down Over 100 Points; Chicago PMI Drops Further
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Monday. 
Via Benzinga
Hoth Therapeutics (NASDAQ: HOTH) Releases BioLexa Phase 1B Trial Results Showing Positive Results in Treating Mild to Moderate Atopic Dermatitis
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
Hoth Therapeutics' Atopic Dermatitis Candidate Shows Improvement In Severity, Shares Jump
Hoth Therapeutics Inc (NASDAQ: HOTH) announced Phase 1b trial data for BioLexa in adult patients with mild-to-moderate atopic dermatitis. 
Via Benzinga
What's Going On With Hoth Therapeutics Stock?
Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading higher Monday after the company announced positive BioLexa Phase 1b clinical trial results. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 53 companies reached new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday, 125 stocks hit new 52-week lows. 
Via Benzinga
Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday
Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company. 
Via Benzinga
Nasdaq Surges Over 200 Points; General Electric Posts Downbeat Earnings
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 120 companies set new 52-week lows. 
Via Benzinga
Why Crown Holdings Shares Are Trading Lower By Around 22%? Here Are 46 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
S&P 500 Rises Over 1%; General Motors Earnings Top Views
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1.8% on Tuesday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with an overview of the biggest pre-market stock movers on Tuesday and the latest news this morning! 
Via InvestorPlace
Why Qualtrics International Shares Are Trading Sharply Higher; Here Are 23 Stocks Moving Premarket
Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose 43% to $2.16 in pre-market trading. Astellas Pharma Inc. announced plans to invest a total of $50 million to acquire 15% of Taysha Gene... 
Via Benzinga
Why Hoth Therapeutics Shares Are Falling In Monday's After-Hours Session
Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading lower by 11.12% to $0.29 during Monday's after-hours session after the company  
Via Benzinga
Hoth Therapeutics And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones jumped by around 197 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around... 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
U.S. Stocks Turn Higher; PepsiCo Posts Upbeat Q2 Results
U.S. stocks turned higher midway through trading after recording losses in the previous session. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.